ROS Therapeutics ApS: Financial statements 2019
CVR: 39507501
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
ROS Therapeutics ApS (CVR 39507501) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -2,140,000 and a net result of DKK -1,883,000. Equity in the 2019 report amounted to DKK 5,026,000. The solvency ratio was 98.8%.
- Gross Profit
- DKK -2,140,000
- Profit/Loss
- DKK -1,883,000
- Equity
- DKK 5,026,000
- Total Assets
- DKK 5,087,000
- Employees
- 0
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
ROS Therapeutics ApS has published its interim report for the period April 23, 2018 – December 31, 2018.
As of May 3, 2019, Ricki Boye has joined the board of directors of ROS Therapeutics ApS.
As of May 3, 2019, Anker Gunvald Lundemose has left the board of directors of ROS Therapeutics ApS.
As of May 3, 2019, Mads Hartvig Clausen has left the board of directors of ROS Therapeutics ApS.
As of May 3, 2019, Jon Bondebjerg has left the board of directors of ROS Therapeutics ApS.
About ROS Therapeutics ApS
ROS Therapeutics ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2018. The company is in liquidation. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Hanne Damgaard Jensen. The company is owned by Sandlykke A/S, HDJ & LEJ Invest ApS and ROS Therapeutics Holding ApS. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK -543,530 and a net result of DKK -1,212,924 compared with DKK -1,314,915 the year before. Equity in the 2025 report amounted to DKK -7,954,408.